Correlation Between Virax Biolabs and Avalo Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Virax Biolabs and Avalo Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virax Biolabs and Avalo Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Virax Biolabs Group and Avalo Therapeutics, you can compare the effects of market volatilities on Virax Biolabs and Avalo Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virax Biolabs with a short position of Avalo Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virax Biolabs and Avalo Therapeutics.

Diversification Opportunities for Virax Biolabs and Avalo Therapeutics

-0.41
  Correlation Coefficient

Very good diversification

The 3 months correlation between Virax and Avalo is -0.41. Overlapping area represents the amount of risk that can be diversified away by holding Virax Biolabs Group and Avalo Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Avalo Therapeutics and Virax Biolabs is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virax Biolabs Group are associated (or correlated) with Avalo Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Avalo Therapeutics has no effect on the direction of Virax Biolabs i.e., Virax Biolabs and Avalo Therapeutics go up and down completely randomly.

Pair Corralation between Virax Biolabs and Avalo Therapeutics

Given the investment horizon of 90 days Virax Biolabs Group is expected to generate 1.78 times more return on investment than Avalo Therapeutics. However, Virax Biolabs is 1.78 times more volatile than Avalo Therapeutics. It trades about 0.05 of its potential returns per unit of risk. Avalo Therapeutics is currently generating about 0.05 per unit of risk. If you would invest  194.00  in Virax Biolabs Group on August 29, 2024 and sell it today you would earn a total of  8.00  from holding Virax Biolabs Group or generate 4.12% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Virax Biolabs Group  vs.  Avalo Therapeutics

 Performance 
       Timeline  
Virax Biolabs Group 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Virax Biolabs Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.
Avalo Therapeutics 

Risk-Adjusted Performance

4 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Avalo Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Avalo Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Virax Biolabs and Avalo Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Virax Biolabs and Avalo Therapeutics

The main advantage of trading using opposite Virax Biolabs and Avalo Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virax Biolabs position performs unexpectedly, Avalo Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Avalo Therapeutics will offset losses from the drop in Avalo Therapeutics' long position.
The idea behind Virax Biolabs Group and Avalo Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Other Complementary Tools

Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios